Or have they already been?
I don’t expect an answer here really, just putting it out to the internet. (These forums may be read even without having a login.)
“Recent studies have suggested that increase of brain KYNA levels is involved in psychiatric disorders such as schizophrenia and depression. KYNA-producing enzymes have broad substrate specificity for amino acids, and brain uptake of kynurenine (KYN), the immediate precursor of KYNA, is via large neutral amino acid transporters.”
“Ten out of 19 amino acids (specifically, leucine, isoleucine, phenylalanine, methionine, tyrosine, alanine, cysteine, glutamine, glutamate, and aspartate) significantly reduced KYNA formation.”
https://www.ncbi.nlm.nih.gov/m/pubmed/26051411/
“This study adds to the evidence that high levels of kynurenic acid contribute to cognitive dysfunction,” she says. “If we can come up with ways to reduce those levels, we may be able to reduce these symptoms for patients.”
There are KAT inhibitors being studied as drugs for sz (Pfizer had one, guess they will be no longer persuing it, hopefully it gets licensed to someone else.) But if simple, safe, OTC amino acids can reduce KYNA in the brain, why not study those in early sz? Seems like it might prevent some cognitive impairment. Obviously it would have to be the correct amino acids. Not just a random mix.